262 related articles for article (PubMed ID: 33089401)
1. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.
Lien HC; Lee YH; Chen IC; Lin CH; Chen TW; Lu YT; Lu YS
Virchows Arch; 2021 Apr; 478(4):669-678. PubMed ID: 33089401
[TBL] [Abstract][Full Text] [Related]
2. Immune parameters associated with survival in metaplastic breast cancer.
Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.
Bagbudar S; Karanlık H; Cabioglu N; Bayram A; Tükenmez M; Aydıner A; Yavuz E; Onder S
Med Oncol; 2023 Dec; 41(1):18. PubMed ID: 38102446
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
5. Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
Sanchez K; Kim I; Chun B; Pucilowska J; Redmond WL; Urba WJ; Martel M; Wu Y; Campbell M; Sun Z; Grunkemeier G; Chang SC; Bernard B; Page DB
Breast Cancer Res; 2021 Jan; 23(1):2. PubMed ID: 33413574
[TBL] [Abstract][Full Text] [Related]
6. Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases.
Voutilainen S; Heikkilä P; Bartkova J; Nevanlinna H; Blomqvist C; Bartek J; Mattson J
BMC Cancer; 2022 Dec; 22(1):1298. PubMed ID: 36503417
[TBL] [Abstract][Full Text] [Related]
7. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
Cimino-Mathews A; Thompson E; Taube JM; Ye X; Lu Y; Meeker A; Xu H; Sharma R; Lecksell K; Cornish TC; Cuka N; Argani P; Emens LA
Hum Pathol; 2016 Jan; 47(1):52-63. PubMed ID: 26527522
[TBL] [Abstract][Full Text] [Related]
10. Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Brcic I; Kluba AM; Godschachner TM; Suppan C; Regitnig P; Dandachi N; Lax SF; Balić M
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614261
[TBL] [Abstract][Full Text] [Related]
11. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Amoils M; Kim J; Lee C; Sunwoo JB; Colevas AD; Aasi SZ; Hollmig ST; Ma Y; Divi V
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):93-99. PubMed ID: 30012051
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma.
Hongo T; Kuga R; Miyazaki M; Komune N; Nakano T; Yamamoto H; Koike K; Sato K; Kogo R; Nabeshima K; Oda Y; Nakagawa T
Laryngoscope; 2021 Dec; 131(12):2674-2683. PubMed ID: 34143491
[TBL] [Abstract][Full Text] [Related]
16. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes.
Ni Y; Tsang JY; Shao Y; Poon IK; Tam F; Shea KH; Tse GM
Oncologist; 2022 Apr; 27(4):e313-e327. PubMed ID: 35380716
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma.
Hoffmann LG; Sarian LO; Vassallo J; de Paiva Silva GR; Ramalho SOB; Ferracini AC; da Silva Araujo K; Jales RM; Figueira DE; Derchain S
Sci Rep; 2021 Nov; 11(1):22478. PubMed ID: 34795307
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
[TBL] [Abstract][Full Text] [Related]
19. Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma.
González-Martínez S; Pérez-Mies B; Pizarro D; Caniego-Casas T; Cortés J; Palacios J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299016
[TBL] [Abstract][Full Text] [Related]
20. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1.
Kalaw E; Lim M; Kutasovic JR; Sokolova A; Taege L; Johnstone K; Bennett J; Saunus JM; Niland C; Ferguson K; Gresshoff I; Bettington M; Pathmanathan N; Tse GM; Papadimos D; Pathmanathan R; Harris G; Yamaguchi R; Tan PH; Fox S; O'Toole SA; Simpson PT; Lakhani SR; McCart Reed AE
Br J Cancer; 2020 Nov; 123(11):1665-1672. PubMed ID: 32939056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
